Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa
Opus Genetics, Inc. (IRD)
Company Research
Source: GlobeNewswire
The trial is funded through Abu Dhabi’s Healthcare Research and Innovation FundClinical development activities will commence at Cleveland Clinic Abu Dhabi in 2026MERTK-related retinitis pigmentosa affects an estimated 60,000 patients worldwide RESEARCH TRIANGLE PARK, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the launch and funding of its clinical trial evaluating a gene therapy for MERTK-related retinitis pigmentosa (RP), a rare inherited eye disease that causes progressive vision loss and eventual blindness. The study is being launched in Abu Dhabi, the capital of the United Arab Emirates in collaboration with the Department of Health – Abu Dhabi (DoH), Cleveland Clinic Abu Dhabi, the Innovative Research Oversight and Support (IROS) division of the M42 group, and the Author
Show less
Read more
Impact Snapshot
Event Time:
IRD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRD alerts
High impacting Opus Genetics, Inc. news events
Weekly update
A roundup of the hottest topics
IRD
News
- Opus Genetics (NASDAQ:IRD) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $7.00 price target on the stock.MarketBeat
- Opus Genetics (NASDAQ:IRD) was upgraded by analysts at BTIG Research to a "strong-buy" rating.MarketBeat
- Opus Genetics (NASDAQ:IRD) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.MarketBeat
- Opus Genetics Highlights 2025 Progress and Upcoming 2026 CatalystsGlobeNewswire
- Opus Genetics (NASDAQ:IRD) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=IRD&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen<MarketBeat
IRD
Sec Filings
- 1/26/26 - Form 4
- 1/26/26 - Form 4
- 1/26/26 - Form 4
- IRD's page on the SEC website